Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari
{"title":"Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer","authors":"Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari","doi":"10.1016/j.clgc.2024.102187","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102187"},"PeriodicalIF":2.7000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001587","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
•
PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.
•
A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.
•
In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.
期刊介绍：
Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
